These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972 [TBL] [Abstract][Full Text] [Related]
3. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients. Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D Front Immunol; 2022; 13():1017863. PubMed ID: 36248803 [TBL] [Abstract][Full Text] [Related]
4. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
5. Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2. Reekie J; Stovring H; Nielsen H; Johansen IS; Benfield T; Wiese L; Stærke NB; Iversen K; Mustafa AB; Petersen KT; Juhl MR; Knudsen LS; Iversen MB; Andersen SD; Larsen FD; Baerends EAM; Lindvig SO; Rasmussen LD; Madsen LW; Bannister W; Jensen TO; Dietz LL; Ostrowski SR; Østergaard L; Tolstrup M; Lundgren JD; Søgaard OS; Int J Infect Dis; 2024 Sep; 146():107111. PubMed ID: 38801970 [TBL] [Abstract][Full Text] [Related]
6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
7. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Smith M; Kwatra G; Izu A; Nel A; Cutland C; Ahmed K; Baillie V; Barnabas S; Bhorat Q; Briner C; Lazarus E; Dheda K; Fairlie L; Koen A; Madhi S; Blackburn JM Viruses; 2023 Feb; 15(2):. PubMed ID: 36851662 [TBL] [Abstract][Full Text] [Related]
8. Cohort Profile:The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE). Stærke NB; Reekie J; Johansen IS; Nielsen H; Benfield T; Wiese L; Søgaard OS; Tolstrup M; Iversen KK; Tarp B; Larsen FD; Larsen L; Lindvig SO; Holden IK; Iversen MB; Knudsen LS; Fogh K; Jakobsen ML; Traytel AK; Ostergaard L; Lundgren J; BMJ Open; 2022 Dec; 12(12):e069065. PubMed ID: 36585137 [TBL] [Abstract][Full Text] [Related]
9. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
11. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days. Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC Front Immunol; 2021; 12():786554. PubMed ID: 35003104 [TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
13. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088 [TBL] [Abstract][Full Text] [Related]
14. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205 [TBL] [Abstract][Full Text] [Related]
15. Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. Huang CF; Jang TY; Wu PH; Kuo MC; Yeh ML; Wang CW; Liang PC; Wei YJ; Hsu PY; Huang CI; Hsieh MY; Lin YH; Hsiao HH; Hsu CM; Huang CT; Lee CY; Chen YH; Chen TC; Lin KD; Wang SH; Wang SF; Huang JF; Dai CY; Chuang WL; Yu ML Virol J; 2023 Jun; 20(1):112. PubMed ID: 37268999 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis. Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256 [TBL] [Abstract][Full Text] [Related]
17. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
19. Natural infection versus hybrid (natural and vaccination) humoral immune response to SARS-CoV-2: a comparative paired analysis. AbdelWareth L; Alhousani F; Abuyadek R; Donnelly J; Leinberger-Jabari A; Atef S; Al-Rifai RH Front Immunol; 2023; 14():1230974. PubMed ID: 37720219 [TBL] [Abstract][Full Text] [Related]
20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]